Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)

Summary of Results

Shin Nippon Biomedical Laboratories, Ltd. centered on its CRO business achieved record interim net sales of 17,568 million yen, a 19.0% increase year-on-year. Operating income rose substantially to 1,555 million yen, ordinary income reached 3,081 million yen, and interim net income attributable to owners of parent expanded to 2,197 million yen. Contributing factors included timing shifts in revenue recognition within the CRO business and deferral of expenses in the TR business, along with increased global orders. The growing proportion of overseas operations and costs related to product development by Satsuma Co. also had an impact.

Forward Policy and Financial Position

Through supplementary financial materials and an earnings briefing, the company maintained its full-year forecasts for the fiscal year ending March 2027 while monitoring foreign exchange trends and the effects of timing differences. On the financial side, total assets were 109,364 million yen, equity ratio was 36.1%, and shareholders' equity was 39,818 million yen, maintaining stability. In the financial notice, the dividend policy assumes a year-end dividend of 20 yen and a full-year total of 50 yen, with no change to dividend forecasts. Cash and cash equivalents increased to 24,270 million yen at the interim period end.